Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DLCO

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    305 result(s) found for: DLCO. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-002114-40 Sponsor Protocol Number: APHP200527 Start Date*: 2020-07-30
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Nintedanib for the treatment of SARS-Cov-2 induced pulmonary fibrosis
    Medical condition: Patients 2 to 6 months after Covid-19 acute pneumonia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002825-10 Sponsor Protocol Number: NACoV Start Date*: 2022-01-17
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Exploratory efficacy of N-Acetylcysteine in patients with history of COVID-19 (NACoV)
    Medical condition: patients with history of SARS-Cov-2 infection and residual respiratory impairment
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10058686 Bilateral pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001134-11 Sponsor Protocol Number: 1305-0023 Start Date*: 2022-11-22
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Medical condition: Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038738 - Respiratory, thoracic and mediastinal disorders 10084309 Progressive fibrosing interstitial lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) EE (Trial now transitioned) FI (Trial now transitioned) SI (Trial now transitioned) SE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020688-18 Sponsor Protocol Number: CQAX576A2203 Start Date*: 2011-06-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in pa...
    Medical condition: Patients with rapidly progressive idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003687-78 Sponsor Protocol Number: IPF/LANREOTIDE/2011-01 Start Date*: 2012-02-21
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005269-37 Sponsor Protocol Number: 836021009 Start Date*: 2014-10-02
    Sponsor Name:St. Antonius Hospital
    Full Title: RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS
    Medical condition: Patients with rare Immune mediated inflammatory diseases (IMIDs) involving the lungs causing interstitial pneumonitis (IP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001263-85 Sponsor Protocol Number: SAV006-05 Start Date*: 2021-07-19
    Sponsor Name:Savara ApS
    Full Title: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP).
    Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IE (Trial now transitioned) DE (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) RO (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001816-56 Sponsor Protocol Number: HUM 05-064 Start Date*: 2006-05-11
    Sponsor Name:Rigshospitalet
    Full Title: Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)?
    Medical condition: sarcoidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002224-26 Sponsor Protocol Number: INFLIXIMABDOSE01 Start Date*: 2015-05-07
    Sponsor Name:St. Antonius Hospital
    Full Title: A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment
    Medical condition: Sarcoidosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004148-31 Sponsor Protocol Number: PREDMETH_NL71782.078.19 Start Date*: 2020-02-26
    Sponsor Name:Erasmus Medisch Centrum Dept. of Pulmonology
    Full Title: The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
    Medical condition: pulmonary sarcoidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003878-33 Sponsor Protocol Number: MOL-PAP-002 Start Date*: 2016-01-28
    Sponsor Name:Savara ApS
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients
    Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) NL (Completed) DE (Completed) GR (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001527-11 Sponsor Protocol Number: Protocol H7U-MC-IDAS Start Date*: 2005-08-17
    Sponsor Name:Eli Lilly and Company
    Full Title: A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma
    Medical condition: Patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus require daily use of insulin for the maintenance of normal glucose homeostasis. At present, insulin can be de...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003629-16 Sponsor Protocol Number: BEB Start Date*: 2015-03-10
    Sponsor Name:University Hospital/Inselspital Berne, Department for Medical Oncology
    Full Title: A randomized phase II trial comparing BeEAM with BEAM as conditioning regimen for autologous stem cell transplantation (ASCT) in lymphoma patients (BEB-trial).
    Medical condition: Chemosensitive diffuse large B-cell lymphomas (DLBCL), follicular lymphomas (FL), and mantle cell lymphomas (MCL) in first or second remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004088-77 Sponsor Protocol Number: BA2006/03/03 Start Date*: 2007-12-03
    Sponsor Name:BioAlliance Pharma
    Full Title: Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.
    Medical condition: Advanced hepatocarcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000564-14 Sponsor Protocol Number: PIPF-023 Start Date*: 2013-06-18
    Sponsor Name:InterMune International AG.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenid...
    Medical condition: Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000791-38 Sponsor Protocol Number: WA42293 Start Date*: 2021-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Completed) DE (Completed) HU (Completed) GR (Prematurely Ended) FI (Completed) PT (Prematurely Ended) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000247-26 Sponsor Protocol Number: H7U-MC-IDBA(b) Start Date*: 2006-05-18
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glar...
    Medical condition: Male or female nonsmoking patients 18 years of age or older; have had type 2 diabetes mellitus for at least 6 months at study entry and have been treated with one or more oral antihyperglycemic med...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012641 Diabetic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001436-72 Sponsor Protocol Number: MKC-TI-030 Start Date*: 2005-11-24
    Sponsor Name:MannKind Corporation
    Full Title: Pulmonary Outcomes within a 2-year Period in Subjects with Diabetes Mellitus Treated with Technosphere®/Insulin or Antidiabetic Treatment and in Subjects without Abnormalities in Glucose Control
    Medical condition: Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000497-80 Sponsor Protocol Number: H7U-MC-IDAV Start Date*: 2007-07-27
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabete...
    Medical condition: Male or female nonsmoking patients 18 years of age or older who have had type 1 diabetes mellitus for at least 24 months at study entry and are taking at least 2 or 3 preprandial injections per day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000392-28 Sponsor Protocol Number: 1199.214 Start Date*: 2015-11-02
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lu...
    Medical condition: Patients with Systemic Sclerosis and associated Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10012977 Diffuse systemic sclerosis LLT
    19.1 100000004859 10036814 Progressive systemic sclerosis LLT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10042954 Systemic sclerosis pulmonary PT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10025109 Lung involvement in systemic sclerosis LLT
    19.1 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) PT (Completed) DK (Completed) BE (Completed) ES (Completed) GR (Completed) FR (Completed) PL (Completed) IE (Completed) FI (Completed) NO (Completed) SE (Completed) AT (Completed) HU (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:37:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA